These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Antibodies against multiple merozoite surface antigens of the human malaria parasite Plasmodium falciparum inhibit parasite maturation and red blood cell invasion. Woehlbier U; Epp C; Hackett F; Blackman MJ; Bujard H Malar J; 2010 Mar; 9():77. PubMed ID: 20298576 [TBL] [Abstract][Full Text] [Related]
23. Multiprotein complex between the GPI-anchored CyRPA with PfRH5 and PfRipr is crucial for Plasmodium falciparum erythrocyte invasion. Reddy KS; Amlabu E; Pandey AK; Mitra P; Chauhan VS; Gaur D Proc Natl Acad Sci U S A; 2015 Jan; 112(4):1179-84. PubMed ID: 25583518 [TBL] [Abstract][Full Text] [Related]
24. The Structure of the Cysteine-Rich Domain of Plasmodium falciparum P113 Identifies the Location of the RH5 Binding Site. Campeotto I; Galaway F; Mehmood S; Barfod LK; Quinkert D; Kotraiah V; Phares TW; Wright KE; Snijders AP; Draper SJ; Higgins MK; Wright GJ mBio; 2020 Sep; 11(5):. PubMed ID: 32900802 [No Abstract] [Full Text] [Related]
25. High-level expression of the malaria blood-stage vaccine candidate Plasmodium falciparum apical membrane antigen 1 and induction of antibodies that inhibit erythrocyte invasion. Kocken CH; Withers-Martinez C; Dubbeld MA; van der Wel A; Hackett F; Valderrama A; Blackman MJ; Thomas AW Infect Immun; 2002 Aug; 70(8):4471-6. PubMed ID: 12117958 [TBL] [Abstract][Full Text] [Related]
26. A full-length recombinant Plasmodium falciparum PfRH5 protein induces inhibitory antibodies that are effective across common PfRH5 genetic variants. Bustamante LY; Bartholdson SJ; Crosnier C; Campos MG; Wanaguru M; Nguon C; Kwiatkowski DP; Wright GJ; Rayner JC Vaccine; 2013 Jan; 31(2):373-9. PubMed ID: 23146673 [TBL] [Abstract][Full Text] [Related]
27. Plasmodium falciparum merozoite surface protein 1 (MSP-1)-MSP-3 chimeric protein: immunogenicity determined with human-compatible adjuvants and induction of protective immune response. Mazumdar S; Mukherjee P; Yazdani SS; Jain SK; Mohmmed A; Chauhan VS Infect Immun; 2010 Feb; 78(2):872-83. PubMed ID: 19933832 [TBL] [Abstract][Full Text] [Related]
28. The relationship between anti-merozoite antibodies and incidence of Plasmodium falciparum malaria: A systematic review and meta-analysis. Fowkes FJ; Richards JS; Simpson JA; Beeson JG PLoS Med; 2010 Jan; 7(1):e1000218. PubMed ID: 20098724 [TBL] [Abstract][Full Text] [Related]
29. P113 is a merozoite surface protein that binds the N terminus of Plasmodium falciparum RH5. Galaway F; Drought LG; Fala M; Cross N; Kemp AC; Rayner JC; Wright GJ Nat Commun; 2017 Feb; 8():14333. PubMed ID: 28186186 [TBL] [Abstract][Full Text] [Related]
30. Antibodies against a short region of PfRipr inhibit Plasmodium falciparum merozoite invasion and PfRipr interaction with Rh5 and SEMA7A. Nagaoka H; Kanoi BN; Ntege EH; Aoki M; Fukushima A; Tsuboi T; Takashima E Sci Rep; 2020 Apr; 10(1):6573. PubMed ID: 32313230 [TBL] [Abstract][Full Text] [Related]
31. The Plasmodium falciparum erythrocyte invasion ligand Pfrh4 as a target of functional and protective human antibodies against malaria. Reiling L; Richards JS; Fowkes FJ; Wilson DW; Chokejindachai W; Barry AE; Tham WH; Stubbs J; Langer C; Donelson J; Michon P; Tavul L; Crabb BS; Siba PM; Cowman AF; Mueller I; Beeson JG PLoS One; 2012; 7(9):e45253. PubMed ID: 23028883 [TBL] [Abstract][Full Text] [Related]
32. Immunogenicity of a recombinant malaria vaccine candidate, domain I+II of AMA-1 ectodomain, from Indian P. falciparum alleles. Lalitha PV; Biswas S; Pillai CR; Saxena RK Vaccine; 2008 Aug; 26(35):4526-35. PubMed ID: 18590786 [TBL] [Abstract][Full Text] [Related]
33. Immunogenicity of a chimeric Plasmodium falciparum merozoite surface protein vaccine in Aotus monkeys. Burns JM; Miura K; Sullivan J; Long CA; Barnwell JW Malar J; 2016 Mar; 15():159. PubMed ID: 26975721 [TBL] [Abstract][Full Text] [Related]
34. Genetic polymorphisms in malaria vaccine candidate Plasmodium falciparum reticulocyte-binding protein homologue-5 among populations in Lagos, Nigeria. Ajibaye O; Osuntoki AA; Balogun EO; Olukosi YA; Iwalokun BA; Oyebola KM; Hikosaka K; Watanabe YI; Ebiloma GU; Kita K; Amambua-Ngwa A Malar J; 2020 Jan; 19(1):6. PubMed ID: 31906953 [TBL] [Abstract][Full Text] [Related]
35. Antibodies against a Plasmodium falciparum RON12 inhibit merozoite invasion into erythrocytes. Ito D; Takashima E; Yamasaki T; Hatano S; Hasegawa T; Miura K; Morita M; Thongkukiatkul A; Diakite M; Long CA; Sattabongkot J; Udomsangpetch R; Iriko H; Ishino T; Tsuboi T Parasitol Int; 2019 Feb; 68(1):87-91. PubMed ID: 30342119 [TBL] [Abstract][Full Text] [Related]
36. Inhibitory humoral responses to the Plasmodium falciparum vaccine candidate EBA-175 are independent of the erythrocyte invasion pathway. Badiane AS; Bei AK; Ahouidi AD; Patel SD; Salinas N; Ndiaye D; Sarr O; Ndir O; Tolia NH; Mboup S; Duraisingh MT Clin Vaccine Immunol; 2013 Aug; 20(8):1238-45. PubMed ID: 23761656 [TBL] [Abstract][Full Text] [Related]
37. Evidence that invasion-inhibitory antibodies specific for the 19-kDa fragment of merozoite surface protein-1 (MSP-1 19) can play a protective role against blood-stage Plasmodium falciparum infection in individuals in a malaria endemic area of Africa. John CC; O'Donnell RA; Sumba PO; Moormann AM; de Koning-Ward TF; King CL; Kazura JW; Crabb BS J Immunol; 2004 Jul; 173(1):666-72. PubMed ID: 15210830 [TBL] [Abstract][Full Text] [Related]